Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.36 |
| ▸ | MBOAT4 | Q96T53 | 1/20 | 0.35 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.33 |
| ▸ | EGFR | P00533 | 1/20 | 0.33 |
| ▸ | ERBB3 | P21860 | 1/20 | 0.33 |
| ▸ | HCRTR1 | O43613 | 2/20 | 0.32 |
| ▸ | HCRTR2 | O43614 | 2/20 | 0.32 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.32 |
| ▸ | IDH1 | O75874 | 4/20 | 0.32 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.32 |
| ▸ | RXRA | P19793 | 1/20 | 0.32 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.32 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | F2RL3 | Q96RI0 | 1/20 | 0.31 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28980434 | 0.84 | CYP3A4 (0.35) | CYP3A4TSHRL3MBTL1EGFRERBB3 | |
| SCHEMBL10982641 | 0.82 | L3MBTL1 (0.43) | L3MBTL1GRM4MEN1ALDH1A1KMT2A | |
| SCHEMBL425129 | 0.79 | L3MBTL1 (0.40) | CYP3A4TSHRL3MBTL1IDH1MEN1 | |
| SCHEMBL17548201 | 0.77 | GRM4 (0.42) | MBOAT4PDE10AHCRTR1HCRTR2GRM4 | |
| SCHEMBL27869168 | 0.76 | MCHR1 (0.42) | CYP3A4TSHRL3MBTL1EGFRERBB3 | |
| SCHEMBL19510740 | 0.76 | IDH1 (0.42) | CYP3A4TSHRL3MBTL1IDH1ALDH1A1 | |
| SCHEMBL15832227 | 0.75 | CCR1 (0.43) | CYP3A4TSHRMBOAT4PDE10AHCRTR1 | |
| SCHEMBL12093565 | 0.75 | KDR (0.42) | MBOAT4PDE10AHCRTR1HCRTR2IDH1 | |
| SCHEMBL30052574 | 0.75 | MBOAT4 (0.41) | MBOAT4PDE10AHCRTR1HCRTR2GRM4 | |
| SCHEMBL17801501 | 0.75 | MBOAT4 (0.35) | MBOAT4PDE10AHCRTR1HCRTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260028365-A1 | TYROSINE KINASE 2 INHIBITORS AND USES THEREOF | BIOGEN MA INC (US) | 2026-01-29 | — | — | US | disclosed |
| EP-4594318-A1 | AKT1 MODULATORS | Alterome Therapeutics, Inc. (US) | 2025-08-06 | — | — | EP | disclosed |
| US-20250197368-A1 | 2-OXO-DIHYDROQUINOLINE-3-CARBOXAMIDE DERIVATIVES AS GABA TYPE A RECEPTOR MODULATORS | DRAIG THERAPEUTICS LTD. (GB) | 2025-06-19 | — | — | US | disclosed |
| US-20250179045-A1 | LPAR1 ANTAGONISTS AND USES THEREOF | CONTINEUM THERAPEUTICS, INC. | 2025-06-05 | — | — | US | disclosed |
| US-20250092040-A1 | AKT1 MODULATORS | ALTEROME THERAPEUTICS, INC. | 2025-03-20 | — | — | US | disclosed |
| US-20250034110-A1 | LPAR1 ANTAGONISTS AND USES THEREOF | Pipeline Therapeutics, Inc. | 2025-01-30 | — | — | US | disclosed |
| US-20240246932-A1 | ARYL 3-OXOPIPERAZINE CARBOXAMIDES AND HETEROARYL 3-OXOPIPERAZINE CARBOXAMIDES AS NAV1.8 INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2024-07-25 | — | — | US | disclosed |
| US-20240239797-A1 | AKT1 MODULATORS | ALTEROME THERAPEUTICS, INC. | 2024-07-18 | — | — | US | disclosed |
| EP-4380560-A1 | LPAR1 ANTAGONISTS AND USES THEREOF | Contineum Therapeutics, Inc. (US) | 2024-06-12 | — | — | EP | disclosed |
| US-11999730-B1 | AKT1 modulators | ALTEROME THERAPEUTICS, INC. (US) | 2024-06-04 | — | — | US | disclosed |
| EP-2681197-A1 | TETRASUBSTITUTED CYCLOHEXYL COMPOUNDS AS KINASE INHIBITORS | Novartis AG (CH) | 2014-01-08 | — | — | EP | disclosed |
| US-8592629-B2 | Sulfonamide derivatives as Nav 1.7 inhibitors | PFIZER LIMITED (GB) | 2013-11-26 | — | — | US | disclosed |
| EP-2593432-A1 | N-SULFONYLBENZAMIDE DERIVATIVES USEFUL AS VOLTAGE GATED SODIUM CHANNEL INHIBITORS | Pfizer Limited (GB) | 2013-05-22 | — | — | EP | disclosed |
| WO-2012120415-A1 | TETRASUBSTITUTED CYCLOHEXYL COMPOUNDS AS KINASE INHIBITORS | NOVARTIS AG (CH) | 2012-09-13 | — | — | WO | disclosed |
| WO-2012120415-A1 | TETRASUBSTITUTED CYCLOHEXYL COMPOUNDS AS KINASE INHIBITORS | NOVARTIS AG (CH) | 2012-09-13 | — | — | WO | disclosed |
| US-20120225061-A1 | TETRASUBSTITUTED CYCLOHEXYL COMPOUNDS AS KINASE INHIBITORS | NOVARTIS VACCINES AND DIAGNOSTICS, INC. | 2012-09-06 | — | — | US | disclosed |
| US-20120225061-A1 | TETRASUBSTITUTED CYCLOHEXYL COMPOUNDS AS KINASE INHIBITORS | NOVARTIS VACCINES AND DIAGNOSTICS, INC. | 2012-09-06 | — | — | US | disclosed |
| US-20120225061-A1 | TETRASUBSTITUTED CYCLOHEXYL COMPOUNDS AS KINASE INHIBITORS | NOVARTIS VACCINES AND DIAGNOSTICS, INC. | 2012-09-06 | — | — | US | disclosed |
| WO-2012007861-A1 | N-SULFONYLBENZAMIDE DERIVATIVES USEFUL AS VOLTAGE GATED SODIUM CHANNEL INHIBITORS | PFIZER LIMITED (GB) | 2012-01-19 | — | — | WO | disclosed |
| US-20120010183-A1 | Chemical Compounds | PFIZER LIMITED (GB) | 2012-01-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240239797-A1 | AKT1 MODULATORS | AKT1S1, AKT1, AKT2 | CYP3A4 4570/4885TSHR 3990/4885L3MBTL1 801/4885 |
| US-20250179045-A1 | LPAR1 ANTAGONISTS AND USES THEREOF | LPAR1, LPAR2, LPAR3 | CYP3A4 4412/4885TSHR 252/4885L3MBTL1 980/4885 |
| US-20240246932-A1 | ARYL 3-OXOPIPERAZINE CARBOXAMIDES AND HETEROARYL 3-OXOPIPERAZINE CARBOXAMIDES AS NAV1.8 INHIBITORS | TRPV1, SCN8A, SCN2A | CYP3A4 1885/4885TSHR 2980/4885L3MBTL1 4098/4885 |
| US-20250034110-A1 | LPAR1 ANTAGONISTS AND USES THEREOF | LPAR1, LPAR2, LPAR3 | CYP3A4 4412/4885TSHR 252/4885L3MBTL1 980/4885 |
| US-20250197368-A1 | 2-OXO-DIHYDROQUINOLINE-3-CARBOXAMIDE DERIVATIVES AS GABA TYPE A RECEPTOR MODULATORS | GABRA2, GABRA3, GABRB2 | CYP3A4 480/4885TSHR 446/4885L3MBTL1 3823/4885 |
| US-20120010183-A1 | Chemical Compounds | SCN1A, SCN1B, SCN7A | CYP3A4 471/4885TSHR 3372/4885L3MBTL1 4470/4885 |
| US-20250092040-A1 | AKT1 MODULATORS | AKT1S1, AKT1, AKT2 | CYP3A4 4570/4885TSHR 3990/4885L3MBTL1 801/4885 |
| US-11999730-B1 | AKT1 modulators | AKT1S1, AKT1, AKT2 | CYP3A4 4570/4885TSHR 3990/4885L3MBTL1 801/4885 |
| US-20120225061-A1 | TETRASUBSTITUTED CYCLOHEXYL COMPOUNDS AS KINASE INHIBITORS | PIM1, PIM2, PIM3 | CYP3A4 1066/4885TSHR 3502/4885L3MBTL1 3432/4885 |
| US-20260028365-A1 | TYROSINE KINASE 2 INHIBITORS AND USES THEREOF | TYK2, ERBB2, ROS1 | CYP3A4 2650/4885TSHR 469/4885L3MBTL1 3018/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.